Stock Events

Stock Events

Jade Biosciences 

$21.25
0
+$1.5+7.59% Friday 03:45

Statistics

Day High
21.25
Day Low
19.75
52W High
-
52W Low
-
Volume
27
Avg. Volume
-
Mkt Cap
977.59M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q3 2025
Q4 2025
Next
-0.67
-0.6
-0.52
-0.45
Expected EPS
-0.482538
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-139.26MNet Income

Analyst Ratings

29.2Average Price Target
The highest estimate is 39.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow JBIO.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.97B
Vertex Pharmaceuticals is a competitor because it develops and markets therapies for treating cystic fibrosis, a space where Aerovate Therapeutics is also aiming to innovate with its cardiovascular and pulmonary disease treatments.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences is involved in the research and development of drugs for pulmonary diseases among other areas, making it a direct competitor to Aerovate Therapeutics in the pulmonary treatment market.
Arvinas
ARVN
Mkt Cap694.91M
Arvinas, Inc. is focused on developing therapies for cancers and other difficult-to-treat diseases, including lung diseases, which puts it in competition with Aerovate Therapeutics.
Incyte
INCY
Mkt Cap19.12B
Incyte Corporation works on the discovery, development, and commercialization of proprietary therapeutics, including for serious pulmonary conditions, competing with Aerovate Therapeutics.
Galapagos NV
GLPG
Mkt Cap1.91B
Galapagos NV is engaged in the discovery and development of small molecule medicines with novel modes of action, several of which target pulmonary diseases, making it a competitor.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.49B
BioMarin Pharmaceutical Inc. focuses on enzyme replacement therapies and other drug developments for rare genetic diseases, some of which involve pulmonary aspects, competing with Aerovate.
Sarepta Therapeutics
SRPT
Mkt Cap2.22B
Sarepta Therapeutics, Inc. is known for its focus on RNA-targeted therapeutics, including treatments for rare diseases, some of which may overlap with Aerovate Therapeutics' focus areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals, Inc. works on RNAi therapeutics for the treatment of rare diseases, including those affecting the lungs, making it a competitor to Aerovate Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes medicines for the treatment of serious medical conditions, including pulmonary diseases, competing with Aerovate Therapeutics.

About

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Show more...
CEO
ISIN
US0080642061

Listings

XNAS
US
JBIO
BOATS
BOATS
JBIO.BOATS

0 Comments

Share your thoughts

FAQ

What is Jade Biosciences stock price today?▼
The current price of JBIO.BOATS is $21.25 USD — it has increased by +7.59% in the past 24 hours. Watch Jade Biosciences stock price performance more closely on the chart.
What is Jade Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Jade Biosciences stocks are traded under the ticker JBIO.BOATS.
What is Jade Biosciences market cap?▼
Today Jade Biosciences has the market capitalization of 977.59M
When is the next Jade Biosciences earnings date?▼
Jade Biosciences is going to release the next earnings report on May 18, 2026.
What were Jade Biosciences earnings last quarter?▼
JBIO.BOATS earnings for the last quarter are -0.45 USD per share, whereas the estimation was -0.48 USD resulting in a +6.41% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Jade Biosciences revenue for the last year?▼
Jade Biosciences revenue for the last year amounts to 0 USD.
What is Jade Biosciences net income for the last year?▼
JBIO.BOATS net income for the last year is -139.26M USD.
In which sector is Jade Biosciences located?▼
Jade Biosciences operates in the Other sector.
When did Jade Biosciences complete a stock split?▼
Jade Biosciences has not had any recent stock splits.